Advertisement

Topics

Study of Tetrathiomolybdate in Patients With Wilson Disease

2010-07-15 17:00:00 | BioPortfolio

Summary

OBJECTIVES:

Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.

Description

PROTOCOL OUTLINE: This a double blind, randomized study. Patients are randomized into one of two treatment arms.

Arm I: Patients receive tetrathiomolybdate (TM) 3 times a day with meals and 3 times a day between meals for 8 weeks in the absence of neurologic deterioration or unacceptable toxicity.

Arm II: Patients receive trientine therapy for 8 weeks in the absence of neurologic deterioration and unacceptable toxicity.

Additional therapy (off study): Patients in the TM group may receive maintenance zinc, while those in the trientine group may continue on trientine or switch to zinc.

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Conditions

Wilson Disease

Intervention

tetrathiomolybdate, trientine

Location

University of Michigan
Ann Arbor
Michigan
United States
48109

Status

Completed

Source

National Center for Research Resources (NCRR)

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [27 Associated Clinical Trials listed on BioPortfolio]

A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients

Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease

This is a multicenter, randomized, open-label study with an active standard-of-care comparator (penicillamine)

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

The purpose of this study is to evaluate the safety of combination therapy with vemurafenib and trientine in patients with BRAF mutated metastatic melanoma. Vemurafenib is a drug that is ...

Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects

Wilson Disease (WD) is an autosomal recessive disorder of impaired copper (CU) transport caused by mutations in the ATP7B gene. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class ...

The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment

This is a 24-month study to assess copper (Cu) parameters in subjects with Wilson Disease treated with standard of care (SOC) medications. Data will be collected during routinely scheduled...

PubMed Articles [14387 Associated PubMed Articles listed on BioPortfolio]

Wilson's disease: A 2017 update.

Wilson's disease (WD) is characterised by a deleterious accumulation of copper in the liver and brain. It is one of those rare genetic disorders that benefits from effective and lifelong treatments th...

Getting better with age and time: A look back at the European experience for liver transplantation for pediatric patients with Wilson's disease.

Since the seminal experience of Starzl et al (1), liver transplant (LT) has been performed for Wilson's disease patients with failing livers and more controversially for neurologic disease. The major...

Anesthetic management of cesarean delivery for a parturient with Wilson's disease: A case report.

Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive disorder with a prevalence of 1:50,000 to 1:100,000 live births.

Whole-exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype.

Wilson's disease (WD) is an autosomal recessive disorder associated with disease-causing alterations across the ATP7B gene, with highly variable symptoms and age of onset. We aimed to assess whether t...

Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.

Experience with zinc in treating symptomatic hepatic Wilson's disease (WD) is limited.

Medical and Biotech [MESH] Definitions

3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.

A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.

A cinnamon-colored strain of Long-Evans rats which carries a mutation causing fulminant hepatitis and jaundice, with an associated gross accumulation of copper in the liver. This strain is a model for Wilson's Disease (see HEPATOLENTICULAR DEGENERATION).

An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.

An outbred strain of rats developed in 1915 by crossing several Wistar Institute white females with a wild gray male. Inbred strains have been derived from this original outbred strain, including Long-Evans cinnamon rats (RATS, INBRED LEC) and Otsuka-Long-Evans-Tokushima Fatty rats (RATS, INBRED OLETF), which are models for Wilson's disease and non-insulin dependent diabetes mellitus, respectively.

More From BioPortfolio on "Study of Tetrathiomolybdate in Patients With Wilson Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial